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A B S T R A C T
Purpose
The anti–programmed death-1 antibody pembrolizumab was evaluated in KEYNOTE-028, a multi-
cohort, phase IB study of patients with programmed death ligand-1 (PD-L1)–positive advanced solid
tumors. Results from the esophageal carcinoma cohort are reported herein.
Patients and Methods
Eligible patients with squamous cell carcinoma or adenocarcinoma of the esophagus or gastro-
esophageal junction in whom standard therapy failed and who had PD-L1–positive tumors received
pembrolizumab 10 mg/kg every 2 weeks for up to 2 years or until conﬁrmed disease progression or
intolerable toxicity. Response was assessed every 8 weeks up to 6 months and every 12 weeks
thereafter. Primary end points were safety and overall response rate, determined by investigator
review per Response Evaluation Criteria in Solid Tumors (version 1.1).
Results
Among 83 patientswith esophageal carcinoma and samples evaluable for PD-L1 expression, 37 (45%)
had PD-L1–positive tumors, and 23 were enrolled. Median age was 65 years; 78% had squamous
histology; and 87% received $ two prior therapies for advanced/metastatic disease. As of the data
cutoff (February 20, 2017), median follow-up was 7 months (range, 1 to 33 months). Nine patients (39%)
experienced treatment-relatedadverseevents,most commonlydecreasedappetite, decreased lymphocyte
count, generalized rash, and rash (two patients [9%] each). No grade 4 adverse events or deaths were
attributed to pembrolizumab. Overall response rate was 30% (95%CI, 13% to 53%); median duration
of responsewas 15months (range, 6 to 26months). A six-gene interferon-g gene expression signature
analysis suggested that delayed progression and increased response occur among pembrolizumab-
treated patients with higher interferon-g composite scores.
Conclusion
Pembrolizumab demonstrated manageable toxicity and durable antitumor activity in patients with
heavily pretreated, PD-L1–positive advanced esophageal carcinoma.
J Clin Oncol 36:61-67. © 2017 by American Society of Clinical Oncology
INTRODUCTION
Esophageal carcinoma is the eighth most common
cancer and the sixth leading cause of cancer-related
deaths worldwide, with an estimated 400,000
deaths annually.1,2 It is endemic in developing
countries, where it is the fourth leading cause of
cancer-related deaths.1,2 Prevalence of esophageal
carcinoma is higher inmen than inwomen,1,2 and
the incidence and histologic subtype vary based on
geographic location.3 In the Western Hemisphere,
the incidence of adenocarcinoma has increased
over the past 25 years, mainly in association with
increasing rates of obesity, gastroesophageal
reﬂux disease, and Barrett’s esophagus.3 In con-
trast, in other parts of the world, particularly in the
esophageal cancer belt, which extends from eastern
Turkey through the Middle East to Mongolia and
western/northern China, squamous cell carcinoma
is the dominant histologic subtype, with incidence
declining over the past decades.3 The main risk
factors for squamous cell carcinoma of the esoph-
agus include smoking and alcohol consumption;
other risk factors may include drinking hot bev-
erages and limited inclusion of fruits and vegetables
in the diet.3 Recent genomic analysis has further
shown the differences between histologic subtypes
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of esophageal carcinoma. Adenocarcinomas are fairly homogeneous
and are distinct from squamous cell carcinomas, which include at
least three molecular subtypes.4
No chemotherapeutic regimens or targeted agents are approved
speciﬁcally for the esophageal carcinoma indication. More than half
of patients with esophageal carcinoma present with advanced or
metastatic disease, and treatment is largely palliative, is associated
with substantial toxicity, and has limited survival beneﬁt.5,6 There
are few randomized clinical trials in squamous cell carcinoma or
adenocarcinoma of the esophagus speciﬁcally, and clinicians
usually extrapolate evidence from clinical trials in gastric cancer or
gastroesophageal junction (GEJ) adenocarcinoma to esophageal
carcinoma. For ﬁrst-line treatment of patients with squamous cell
carcinoma or adenocarcinoma of the esophagus, guidelines from
the National Comprehensive Cancer Network recommend che-
motherapy with cisplatin or oxaliplatin combined with ﬂuorouracil
or capecitabine.7 Although addition of epirubicin, irinotecan, and
taxanes can offer some additional beneﬁt, these combination che-
motherapy regimens result in overall response rates (ORRs), 50%,
median overall survival (OS) , 11 months, and substantial
toxicity.7,8 Depending on prior therapy and Eastern Cooperative
Oncology Group (ECOG) performance status, National Compre-
hensive Cancer Network guidelines recommend the vascular endo-
thelial growth factor receptor-2 monoclonal antibody ramucirumab
in combination with paclitaxel or single-agent chemotherapy with
docetaxel or irinotecan as second-line treatment of advanced or
metastatic disease; however, survival beneﬁts with these agents are
modest.7 Regardless of histologic subtype, patients with advanced
or metastatic esophageal carcinoma have a poor prognosis, with
a 5-year OS rate, 15%5,6; therefore, there is a high unmet medical
need for therapies that improve outcomes for these patients.
During normal functioning of the immune system, the
programmed death-1 (PD-1) receptor is expressed on activated
T cells and interacts with its ligands, programmed death ligand-1
(PD-L1) and programmed death ligand-2, to protect healthy cells
from excessive inﬂammatory or autoimmune responses.9-13
Tumor-associated dysregulation of the PD-1 pathway leads to
escape from immune surveillance because tumor cells expressing
PD-L1 can reduce T-cell effector activity and dampen appropriate
immune responses.13-15 In multiple cancer types, host tumor–
inﬁltrating lymphocytes (TILs) mediate PD-L1 expression via
interferon-g secretion.13,14 PD-L1 overexpression has been observed
in up to 40% of squamous cell carcinomas of the esophagus and in
up to 18% of esophageal adenocarcinomas, and although prognosis
is worse for patients with squamous cell carcinoma overexpressing
PD-L1 than for those without PD-L1 expression, the prognostic
impact of PD-L1 expression in esophageal adenocarcinoma is not
well understood.16,17 Furthermore, TIL density correlates with
therapeutic tumor response and survival in esophageal carcinoma,
and TIL composition of the tumor is inversely correlated with
expression levels of negative immune regulators.18-21 Taken together,
the immune checkpoint dysregulation and inﬂamed phenotype
demonstrated in multiple tumor types provides a compelling ra-
tionale for evaluation of immune checkpoint inhibitors in solid
tumors, including esophageal carcinoma.
Pembrolizumab is a high-afﬁnity, humanized immunoglob-
ulin G4-k monoclonal antibody against PD-1 that directly blocks
the interaction between PD-1 and its ligands. Pembrolizumab has
demonstrated robust antitumor activity and a favorable safety
proﬁle in multiple tumor types and is currently approved in more
than 60 countries for the treatment of one or more advanced
malignancies. In addition, PD-L1 expression has been correlated
with a higher treatment response to PD-1 blockade in several
different cancer types.22 Furthermore, immune-related gene ex-
pression signatures, including genes of T-cell function, antigen
presentation, and interferon-g signaling, may be strong predictors
of clinical beneﬁt from pembrolizumab treatment, even among
PD-L1–positive patients.23 Although rare in esophageal carcinoma,
microsatellite instability–high status and presence of Epstein-Barr
virus infection may also affect response to anti–PD-1 therapy.24
Herein, we report the safety, efﬁcacy, and gene expression signature
score of a cohort of patients with recurrent or metastatic PD-
L1–positive carcinoma of the esophagus or GEJ who were treated
with pembrolizumab in the multicohort KEYNOTE-028 study.
PATIENTS AND METHODS
Study Design and Patients
KEYNOTE-028 (ClinicalTrials.gov identiﬁer: NCT02054806) is an
international, multicenter, multicohort, phase IB trial of pembrolizumab
in patients with 20 different types of PD-L1–positive advanced solid tu-
mors with high unmet need. Patients in the esophageal carcinoma cohort
were enrolled at nine investigational sites in France, Japan, the Republic of
Korea, Taiwan, the United Kingdom, and the United States.
Key eligibility criteria for this cohort included age $ 18 years;
measurable disease at baseline on the basis of Response Evaluation Criteria
in Solid Tumors, version 1.1 (RECIST v 1.1); ECOG performance status of
0 or 1; adequate organ (coagulation, hematologic, hepatic, and renal)
function as determined by laboratory tests within 10 days of study
treatment; provision of archival tumor tissue for gene expression proﬁling;
and PD-L1–positive, histologically or cytologically conﬁrmed, locally ad-
vanced, or metastatic squamous cell carcinoma or adenocarcinoma of the
esophagus or GEJ for which prior standard therapy was ineffective or for
which standard therapy did not exist or was not considered appropriate.
Key exclusion criteria were diagnosis of immunodeﬁciency or receipt
of systemic steroid therapy within 7 days before the ﬁrst pembrolizumab
dose; treatment with any anticancer monoclonal antibody within 4 weeks
before the ﬁrst pembrolizumab dose; prior chemotherapy, small-molecule
therapy, or radiation therapy within 2 weeks before the ﬁrst pembrolizumab
dose; active brain metastases; active autoimmune disease that necessitated
systemic treatment in the preceding 2 years; interstitial lung disease; previous
therapy targeting T-cell costimulation or checkpoint pathways; and human
immunodeﬁciency virus, hepatitis B, or hepatitis C infection.
Treatment and Assessments
Patients received pembrolizumab intravenously at a dose of 10 mg/kg
once every 2 weeks for up to 2 years or until conﬁrmed progression,
intolerable toxicity, or patient or investigator decision to discontinue.
Computed tomography or magnetic resonance imaging was performed
every 8 weeks for the ﬁrst 6 months and every 12 weeks thereafter. Re-
sponse was assessed per RECIST v1.1, as assessed by investigator review.
Adverse events (AEs) were reported throughout treatment and for 30 days
after discontinuation (90 days for serious AEs) and were graded according
to the National Cancer Institute Common Terminology Criteria for Ad-
verse Events, version 4.0. AEs of special interest were deﬁned as events with
potentially drug-related immunologic causes that were consistent with an
immune phenomenon, regardless of attribution to treatment or immune
relatedness by the investigator. The primary end points were safety and
ORR by investigator review. ORR was deﬁned as the proportion of patients
who experienced complete response or partial response on the basis of
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RECIST v1.1 at any time during the study; a conﬁrmatory assessment of
response was required per RECIST v1.1. Secondary end points were
progression-free survival (PFS), deﬁned as time from enrollment to ﬁrst
documented disease progression according to RECIST v1.1 or death from
any cause; OS, deﬁned as time from enrollment to death from any cause;
and duration of response (DOR), deﬁned as time from ﬁrst response to
disease progression in patients who achieved partial response or better.
PD-L1 Expression Analysis
PD-L1 expression was assessed at screening by a central laboratory on
the basis of a laboratory-developed prototype immunohistochemical assay
(QualTek Molecular Laboratories, Goleta, CA) using either an archived
(formalin-ﬁxed, parafﬁn-embedded) tumor sample or newly obtained
biopsy sample23 and the 22C3 antibody (Merck, Kenilworth, NJ). PD-L1
positivity was deﬁned as membranous staining on at least 1% of scorable
cells or the presence of a distinctive interface pattern in both neoplastic
cells and contiguous mononuclear inﬂammatory cells.25
Gene Expression Profiling
Tumor tissue was collected at baseline before treatment of a six-gene
interferon-g gene expression signature (CXCL9, CXCL10, HLA-DRA, IDO1,
IFNG, and STAT1) previously found to be associated with response to
pembrolizumab in a melanoma test set26 and subsequently conﬁrmed in
head and neck27 and gastric23 cancer test sets. Samples consisted of
formalin-ﬁxed, parafﬁn-embedded blocks and/or cut tissue on slides. Total
RNA was isolated from samples using the RecoverAll kit (Thermo Fisher
Scientiﬁc, Austin, TX), and RNA was quantiﬁed using the NanoDrop
ND1000 spectrophotometer (Thermo Fisher Scientiﬁc, Wilmington,
DE). The six-gene interferon-g gene expression signature was calculated as
the arithmetic average of the log ratio of the counts of the predictor genes
to the geometric mean of the counts of a set of 11 housekeeping nor-
malization genes. Tests of association between the interferon-g signature
score and PFS and ORR were based on Cox and logistic regression
modeling.
Study Oversight
The study protocol (No. MK-3475-028-02) and all amendments were
approved by the appropriate institutional review boards and ethics committees
at each participating institution. The study was conducted in accordance with
the protocol, Good Clinical Practice guidelines, and the ethical principles
outlined in the Declaration of Helsinki. All patients provided written informed
consent to participate.
Statistical Analyses
Per protocol, multiple interim analyses could be performed because
of the sequential design of the study. A sequential monitoring procedure
was used to evaluate efﬁcacy and futility after at least six patients had at
least one postbaseline response assessment. Enrollment continued provided
at least one of the ﬁrst six patients responded. A sample size of 22 evaluable
patients in this cohort was calculated, using the binomial exact method,
to provide 80% power to demonstrate that the best ORR exceeded 10% at
an overall one-sided 8% a level if the true ORR was 35%. The efﬁcacy
analysis population included all patients with measurable disease at
Table 1. Baseline Demographics and Clinical Characteristics (N = 23)
Characteristic No. (%)
Median age, years (range) 65 (26-71)
Sex
Male 19 (83)
Female 4 (17)
Race
Asian 12 (52)
White 7 (30)
Black or African American 1 (4)
Not speciﬁed 3 (13)
ECOG performance status
0 8 (35)
1 15 (65)
Baseline lactate dehydrogenase level
Normal 17 (74)
Elevated 6 (26)
Histology at baseline
Squamous cell carcinoma 18 (78)
Adenocarcinoma 5 (22)
Prior radiation therapy 14 (61)
Prior (neo)adjuvant systemic therapy 6 (26)
Prior lines of therapy for advanced/metastatic disease
0 1 (4)*
1 2 (9)
2 9 (39)
$ 3 11 (48)
Type of prior therapy†
Platinum 23 (100)
Fluoropyrimidine 21 (91)
Taxane 17 (74)
Epirubicin 3 (13)
Irinotecan 3 (13)
Trastuzumab 1 (4)
Abbreviation: ECOG, Eastern Cooperative Oncology Group.
*This patient received prior (neo)adjuvant therapy with oxaliplatin, ﬂuorouracil,
and levoleucovorin calcium for advanced/metastatic disease.
†Includes therapy given in the (neo)adjuvant setting. Patients could have re-
ceived $ 1 type of prior therapy. Not all prior therapies are listed.
Table 2. Treatment-Related AEs (N = 23)
AE
Grade 1 or 2
No. (%)
Grade 3
No. (%)*
Asthenia 1 (4) 0
Decreased appetite 1 (4) 1 (4)
Decreased lymphocyte count 0 2 (9)
Decreased WBC count 1 (4) 0
Dehydration 1 (4) 0
Dental caries 1 (4) 0
Fatigue 1 (4) 0
Hyperthyroidism 1 (4) 0
Hypothyroidism 1 (4) 0
Increased lacrimation 1 (4) 0
Liver disorder 0 1 (4)
Pemphigoid 1 (4) 0
Pneumonia 1 (4) 0
Pruritus 1 (4) 0
Rash 2 (9)† 1 (4)‡
Stomatitis 1 (4) 0
Abbreviation: AE, adverse event.
*There were no grade 4 treatment-related AEs.
†Includes rash and generalized rash.
‡Generalized rash.
Table 3. Best Overall Response per Response Evaluation Criteria in Solid
Tumors, Version 1.1, Assessed by Investigator Review (N = 23)
Response No. % 95% CI
Overall response rate 7 30 13 to 53
Complete response 0 0 0 to 15
Partial response 7 30 13 to 53
Stable disease 2 9 1 to 28
Progressive disease 13 57 35 to 77
Nonevaluable 1 4 , 1 to 22
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baseline (according to RECIST v1.1) who received at least one dose of
pembrolizumab. The safety analysis population included all patients who
received at least one dose of pembrolizumab. The truncated sequential
probability test was used to evaluate ORR. The Kaplan-Meier method was
used to estimate PFS, OS, and DOR. SAS, version 9.3 (SAS Institute, Cary,
NC), or R, version 3.1.3, was used for all analyses. The data cutoff date for
all analyses presented herein was February 20, 2017.
RESULTS
PD-L1 Expression and Baseline Characteristics
Samples were evaluable for assessment of tumor PD-L1 ex-
pression in 83 of the 90 patients screened (Appendix Fig A1, online
only). Thirty seven (45%) of these samples were determined to be
PD-L1–positive using a prototype immunohistochemical assay.
Among the patients with PD-L1–positive tumors, 14 did not meet
the inclusion criteria for the trial, most commonly because they
declined study participation (n = 6) or did not have an ECOG
performance status of 0 or 1 (n = 5). The other 23 patients were
enrolled from March to July 2014.
Median age was 65 years, 83% of patients were men, and 78%
had squamous cell carcinoma histology (Table 1). More than half
the patients (61%) had received previous radiation therapy. All but
one patient had received previous therapy for advanced/metastatic
disease; 87% had received at least two previous therapies for
advanced/metastatic disease, and all patients had received platinum-
based therapy for early-stage or advanced/metastatic disease. As of the
data cutoff date, median follow-up duration was 7 months (range,
1 to 33 months) and 21 patients (91%) had discontinued treatment,
most commonly for progressive disease (57%) and AEs (9%).
Safety
All 23 patients were included in the safety analysis pop-
ulation. All-grade treatment-related AEs occurred in nine patients
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(39%; Table 2), most commonly rash/generalized rash in three pa-
tients (13%) and decreased appetite and decreased lymphocyte count
in two patients (9%) each. Grade 3 treatment-related AEs occurred in
four patients (17%; Table 2) and included decreased lymphocyte
count in two patients (9%) and decreased appetite, liver disorder, and
generalized rash in one patient (4%) each. All of the grade 3
treatment-related AEs resolved with either discontinuation (for liver
disorder), no action taken (for decreased appetite and one event of
decreased lymphocyte count), or dose interruption (for one event of
decreased lymphocyte count and for generalized rash). The grade 3
treatment-related AE of generalized rash was considered a prespeciﬁed
immune-related AE and occurred on day 19 after initiation of
pembrolizumab treatment. There were no grade 4 treatment-related
AEs. Treatment-related serious AEs occurred in three patients (13%),
namely, grade 2 pemphigoid, grade 3 decreased appetite, and grade 3
liver disorder in one patient each; all resolved with either discon-
tinuation (for liver disorder) or no action taken (for pemphigoid and
decreased appetite). No patients died because of a treatment-related
AE. AEs of special interest, regardless of attribution to treatment or
immune relatedness by the investigator, occurred in six patients (26%)
and included hypothyroidism in two patients (9%) and adrenal in-
sufﬁciency, enterocolitis, hyperthyroidism, and generalized rash (as
described previously) in one patient (4%) each.
Antitumor Activity
All 23 patients were included in the efﬁcacy analysis pop-
ulation. On the basis of RECIST v1.1 by investigator review, ORR
was 30% (95% CI, 13% to 53%; Table 3). All seven responses were
conﬁrmed partial responses. Among the seven patients with a con-
ﬁrmed partial response, three (43%) had received prior radiation
therapy. There was no discernible pattern with regard to previous
chemotherapy regimen (type, time, or schedule) among the seven
patients with a conﬁrmed partial response. Two additional patients
experienced conﬁrmed stable disease. Responses were observed in
patients with both squamous and adenocarcinoma histology. By
histologic subtype, ORR was 28% (ﬁve of 18 patients) for patients
with squamous cell carcinoma and 40% (two of ﬁve patients) for
those with adenocarcinoma. Twelve patients (52%) experienced
a decrease from baseline in target lesion burden (Fig 1A), which
was generally maintained across subsequent tumor assessments
(Fig 1B). The median decrease from baseline in target lesion
burden for the 12 patients who experienced tumor shrinkage
was 244.7% (range, 277.7% to 22.7%).
For the seven patients with a partial response, determined by
investigator review, median time to initial response was 4 months
(range, 2 to 8 months) and median DOR was 15 months (range,
6 to $ 26 months). Patients who experienced a partial response
most commonly had target lesions in the lungs (n = 4), lymph
nodes (n = 3), and liver (n = 2). At the time of analysis, one of the
seven partial responses was ongoing, but all of the patients had
discontinued treatment (Fig 1C).
On the basis of investigator review, median PFSwas 1.8 months
(95% CI, 1.7 to 2.9 months), and the 6-month and 12-month PFS
rates were 30% and 22%, respectively (Fig 2A). Median OS was
7.0 months (95% CI, 4.3 to 17.7 months), and the 6-month and
12-month OS rates were 60% and 40%, respectively (Fig 2B).
The pattern of PFS according to the six-gene interferon-g gene
expression signature score is shown in Figure 3. The signature score
showed trends toward an association with PFS (P = .053, one-
sided) and ORR (P = .107, one-sided) in patients treated with
pembrolizumab.
DISCUSSION
There is a high unmet need for effective and well-tolerated
treatments for patients with advanced esophageal carcinoma.
The overall safety proﬁle in this study of patients with recurrent or
metastatic PD-L1–positive esophageal carcinoma was similar to
that previously reported for pembrolizumab in patients with other
advanced malignancies,22,23,25-29 and no unexpected treatment-
related AEs occurred. Because the anti–PD-1 antibody pem-
brolizumab targets immune cells and not tumor cells, and because
of the activity of pembrolizumab monotherapy previously ob-
served in patients with both squamous cell and adenocarcinoma
histology in other tumor types, including gastric, head and neck,
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and non–small-cell lung cancer,23,27,29 we expected antitumor
activity in esophageal cancer regardless of histologic subtype;
therefore, patients with both squamous cell carcinoma and ade-
nocarcinoma (including GEJ) of the esophagus were enrolled in
this cohort. Pembrolizumab was associated with promising
preliminary antitumor activity and manageable toxicity in patients
with PD-L1–positive, heavily pretreated, advanced esophageal car-
cinoma. Overall, tumor shrinkage from baseline in target lesions
occurred in more than half the patients. Similar to other tumor
types, the extent of response to pembrolizumab varied by his-
tologic subtype, with 40% of patients with adenocarcinoma and
28% of patients with squamous cell carcinoma experiencing
a partial response, for an overall ORR of 30% (95% CI, 13% to
53%). Responses occurred early, with a median time to initial
response of 4 months (range, 2 to 8 months), and were durable,
with a median DOR of 15 months (range, 6 to$ 26 months). Even
patients with stable disease experienced initial tumor shrinkage at
ﬁrst radiologic assessment, which was not indicative of pseu-
doprogression. Among those patients who did have progressive
disease, they were mainly cases of primary resistance. Because of
the small number of patients with adenocarcinoma, conclusions
regarding PFS or OS by histologic subtype are not possible.
Antitumor activity of the anti–PD-1 antibody nivolumab was also
recently shown in a phase II study in which 17% of patients
(n = 65) with PD-L1 unselected treatment-refractory squamous
cell carcinoma of the esophagus had a centrally assessed objective
response.30
On the basis of evidence of the involvement of the PD-1/PD-L1
pathway in esophageal carcinoma,16,18 tumor PD-L1 positivity
was an enrollment criterion in this study. Among patients screened
for enrollment, 45% had PD-L1–positive tumors as determined by
a prototype immunohistochemistry assay, supporting a role for this
pathway in at least a subset of esophageal carcinomas. Similar to
results from other studies of immune checkpoint inhibition in
various tumor types,22,23,29 only a subset of patients with PD-
L1–positive esophageal cancer showed clinical beneﬁt from PD-1
blockade in this study, suggesting that additional biomarkers may
be necessary for reliable prediction of clinical response to pem-
brolizumab. On the basis of a six-gene interferon-g gene ex-
pression signature analysis of CXCL9, CXCL10, HLA-DRA, IDO1,
IFNG, and STAT1, delays in progression and increased clinical
response tended to occur among pembrolizumab-treated patients
with esophageal carcinoma and higher signature scores, consistent
with ﬁndings published for head and neck and gastric cancer.23,27
However, there were limitations to this analysis, including a small
sample size, variability in tissue biopsy storing conditions, and
potential sampling bias and heterogeneity. These preliminary re-
sults regarding the potential predictive value of gene expression
signature for pembrolizumab activity in esophageal carcinoma will
therefore require additional exploration in a larger patient pop-
ulation. In addition, because all patients enrolled in KEYNOTE-
028 had tumors with some degree of PD-L1 expression (as
demonstrated by the prototype assay), this study cannot provide
information on the potential activity of pembrolizumab in patients
with advanced esophageal carcinoma and truly PD-L1–negative
tumors.
In conclusion, pembrolizumab demonstrated promising
preliminary antitumor activity and a manageable safety proﬁle in
this heavily pretreated population of patients with PD-L1–positive
advanced squamous cell carcinoma or adenocarcinoma of the
esophagus enrolled in KEYNOTE-028. Evaluation of pem-
brolizumab for the treatment of esophageal carcinoma is ongoing.
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Appendix
Patients with tumor samples 
evaluable for PD-L1 expression 
(n = 83; 92%)
Patients without tumor samples 
evaluable for PD-L1 expression 
(n = 7; 8%)
Patients with 
PD-L1–negative tumors 
(n = 46; 55%)
Patients with 
PD-L1–positive tumors 
(n = 37; 45%)
Patients enrolled 
(n = 23; 62%)
Patients screened 
(n = 90)
Patients who did not meet 
study inclusion criteria 
(n = 14; 38%)
Fig A1. Patient disposition. PD-L1, programmed death ligand 1.
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